Background: Psoriasis is a chronic inflammatory skin disease characterized by red scaly plaques, which may occur on any site of the body; prevalence is about 2–3% in population. Lipocalin-2 has been recently identified as an adipokine present in the circulation,it is related to insulin resistance, obesity, atherosclerotic diseases and type 2 diabetes. Lipocalin-2 is assumed to be closely associated with the metabolic syndrome in addition to their role in innate immune response to bacterial infection, role in renal injury and in apoptosis. Objective: The aim of the present study is to estimate the level of lipocalin-2 in the serum and tissue of psoriatic patients and to correlate these levels with markers of the metabolic syndrome and disease severity.Patients and methods: This study was done on 30 of psoriasis patients and 30 healthy controls. All patients and controls were subjected to clinical examination in which height, weight, body mass index, waist circumference and blood pressure were measured. Also serum ,tissue levels of lipocalin and CRP were done by ELISA technique . Lipid profile and fasting blood sugar were measured using regular laboratory methods.Results: In this study we detected that tissue lipocalin is more specific to psoriasis than serum lipocalin. No correlation was detected between tissue and serum levels of lipocalin with age of onset, duration, extent and PASI score. Also there was no correlation in tissue and serum levels of lipocalin with metabolic syndrome and related disorders. In conclusion from this work, Egyptian patients with psoriasis are at increased risk of metabolic and cardiovascular complications, compared to the general population. Further studies are required to detect the role of lipocalin-2 in the pathogenesis of psoriasis.